
PTCT
PTC Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
46.430
Open
45.430
VWAP
44.32
Vol
1.51M
Mkt Cap
3.44B
Low
43.175
Amount
66.76M
EV/EBITDA(TTM)
4.30
Total Shares
76.70M
EV
3.85B
EV/OCF(TTM)
5.47
P/S(TTM)
1.95
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
169.98M
-85.55%
--
--
206.02M
-3.36%
--
--
188.13M
-4.4%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for PTC Therapeutics, Inc. (PTCT) for FY2025, with the revenue forecasts being adjusted by 8.83% over the past three months. During the same period, the stock price has changed by -5.89%.
Revenue Estimates for FY2025
Revise Upward

+8.83%
In Past 3 Month
Stock Price
Go Down

-5.89%
In Past 3 Month
15 Analyst Rating

59.03% Upside
Wall Street analysts forecast PTCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 68.86 USD with a low forecast of 46.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
5 Hold
0 Sell
Moderate Buy

59.03% Upside
Current: 43.300

Low
46.00
Averages
68.86
High
120.00

59.03% Upside
Current: 43.300

Low
46.00
Averages
68.86
High
120.00
Wells Fargo
Overweight
maintain
$78 -> $79
2025-08-08
New
Reason
Wells Fargo
Price Target
$78 -> $79
2025-08-08
New
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on PTC Therapeutics to $79 from $78 and keeps an Overweight rating on the shares. Incremental color from the call points to a positive early launch of Sephience, the firm says. Nearer-term vatiquinone's potential approval could be another source of upside, though there remains debate on this program, Wells adds.
RBC Capital
Outperform
maintain
$60 -> $63
2025-08-08
New
Reason
RBC Capital
Price Target
$60 -> $63
2025-08-08
New
maintain
Outperform
Reason
RBC Capital raised the firm's price target on PTC Therapeutics to $63 from $60 and keeps an Outperform rating on the shares after its Q2 results. Translarna remains resilient and should help bridge the company into what the firm expects will be a strong Sephience launch, the analyst tells investors in a research note.
TD Cowen
Joseph Thome
Hold
maintain
$52 -> $56
2025-08-08
New
Reason
TD Cowen
Joseph Thome
Price Target
$52 -> $56
2025-08-08
New
maintain
Hold
Reason
TD Cowen analyst Joseph Thome raised the firm's price target on PTC Therapeutics to $56 from $52 and keeps a Hold rating on the shares. The firm noted Sephience crossed the regulatory finish line and has launched in the U.S./EU. The launch trajectory will be closely watched and be the main stock driver in the near/medium term as the DMD franchise draws back.
Baird
Joel Beatty
Outperform
to
Outperform
downgrade
$72 -> $70
2025-08-08
New
Reason
Baird
Joel Beatty
Price Target
$72 -> $70
2025-08-08
New
downgrade
Outperform
to
Outperform
Reason
Baird analyst Joel Beatty lowered the firm's price target on PTC Therapeutics to $70 from $72 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results where management gave encouraging commentary on PKU launch.
JPMorgan
maintain
$67 -> $68
2025-08-07
New
Reason
JPMorgan
Price Target
$67 -> $68
2025-08-07
New
maintain
Reason
JPMorgan raised the firm's price target on PTC Therapeutics to $68 from $67 and keeps an Overweight rating on the shares. The firm's checks with physicians and payer access experts indicate solid demand for Sephience in phenylketonuria.
Barclays
Gena Wang
Equal Weight
maintain
$42 -> $46
2025-07-29
Reason
Barclays
Gena Wang
Price Target
$42 -> $46
2025-07-29
maintain
Equal Weight
Reason
Barclays analyst Gena Wang raised the firm's price target on PTC Therapeutics (PTCT) to $46 from $42 and keeps an Equal Weight rating on the shares. The company's Sephience received FDA approval in phenylketonuria, with a largely comparable label to BioMarin's (BMRN) Kuvan and a slightly different safety profile, the analyst tells investors in a research note. However, Sephience's pricing of $490,000 is at a "huge premium" versus Kuvan, the firm points out.
See All Ratings
Valuation Metrics
The current forward P/E ratio for PTC Therapeutics Inc (PTCT.O) is -10.48, compared to its 5-year average forward P/E of -10.60. For a more detailed relative valuation and DCF analysis to assess PTC Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-10.60
Current PE
-10.48
Overvalued PE
-1.73
Undervalued PE
-19.48
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
13.56
Current EV/EBITDA
9.44
Overvalued EV/EBITDA
206.66
Undervalued EV/EBITDA
-179.53
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
4.48
Current PS
4.82
Overvalued PS
6.15
Undervalued PS
2.80
Financials
Annual
Quarterly
FY2025Q2
YoY :
-4.19%
178.88M
Total Revenue
FY2025Q2
YoY :
+4.50%
-34.86M
Operating Profit
FY2025Q2
YoY :
-34.61%
-64.85M
Net Income after Tax
FY2025Q2
YoY :
-35.66%
-0.83
EPS - Diluted
FY2025Q2
YoY :
-16.52%
-59.65M
Free Cash Flow
FY2025Q2
YoY :
+1.33%
91.35
Gross Profit Margin - %
FY2025Q2
YoY :
-374.44%
39.52
FCF Margin - %
FY2025Q2
YoY :
-31.76%
-36.25
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 346.51% over the last month.
Sold
0-3
Months
680.1K
USD
2
3-6
Months
6.1M
USD
11
6-9
Months
13.3M
USD
37
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 3181.08% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.7M
Volume
1
6-9
Months
317.9K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
669.3K
Volume
Months
6-9
1
20.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 346.51% over the last month.
Sold
0-3
Months
680.1K
USD
2
3-6
Months
6.1M
USD
11
6-9
Months
13.3M
USD
37
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PTCT News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
16:07:05
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06)

2025-08-07
16:07:03
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06)

2025-07-28 (ET)
2025-07-28
16:21:14
PTC Therapeutics announces FDA approval of Sephience for treatment of PKU

Sign Up For More Events
Sign Up For More Events
News
8.0
08-11NASDAQ.COMNoteworthy Monday Option Activity: ADBE, PTCT, RUM
7.0
08-08SeekingAlphaPTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches
3.0
08-05NASDAQ.COMLook Under The Hood: FELG Has 10% Upside
Sign Up For More News
People Also Watch

FORM
FormFactor Inc
28.230
USD
-1.22%

SNEX
StoneX Group Inc
89.410
USD
+0.09%

ATHM
Autohome Inc
28.550
USD
-0.31%

REZI
Resideo Technologies Inc
27.470
USD
+0.66%

ASH
Ashland Inc
51.590
USD
-0.86%

CNXC
Concentrix Corp
45.940
USD
-2.44%

RYTM
Rhythm Pharmaceuticals Inc
94.310
USD
+2.53%

STR
Sitio Royalties Corp
18.170
USD
-1.41%

DLO
Dlocal Ltd
10.650
USD
-2.92%

AMBA
Ambarella Inc
64.360
USD
-0.29%
FAQ

What is PTC Therapeutics Inc (PTCT) stock price today?
The current price of PTCT is 43.3 USD — it has decreased -4.58 % in the last trading day.

What is PTC Therapeutics Inc (PTCT)'s business?

What is the price predicton of PTCT Stock?

What is PTC Therapeutics Inc (PTCT)'s revenue for the last quarter?

What is PTC Therapeutics Inc (PTCT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for PTC Therapeutics Inc (PTCT)'s fundamentals?

How many employees does PTC Therapeutics Inc (PTCT). have?
